Abstract：【Objective】To explore the efficacy of Shenmai Injection combined with Entecavir in the treatment of patients with hepatitis B-related compensated cirrhosis and its impact on immunological indicators.【Methods】 Seventy-eight patients with hepatitis B-related compensated cirrhosis were randomly divided into an observation group and a control group, each consisting of 39 patients. The control group received Entecavir treatment, while the observation group was treated with Shenmai Injection combination with Entecavir. The efficacy of the treatments was compared between the two groups, along with liver fibrosis indicators [Type Ⅳ Collagen (Ⅳ-C), Laminin (LN)], liver function indicators [Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT)], immunological indicators before and after treatment, and the incidence of adverse reactions.【Results】 The total effective rate in the observation group was 94.87% (37/39), which was higher than the 76.92% (30/39) in the control group, with a statistically significant difference (P<0.05). After treatment, the levels of Ⅳ-C, LN, AST, and ALT in both groups were reduced compared to before treatment (P<0.05), and the levels in the observation group were lower than those in the control group (P<0.05). The levels of both Th17/Treg and CD8+ in two groups decreased after treatment compared to before treatment (P<0.05), and the Th17/Treg and CD8+ levels in the observation group were lower than those in the control group (P<0.05). After treatment, the level of CD4+ increased in both groups (P<0.05), while CD4+ level in the observation group was higher than that in the control group (P<0.05). The overall incidence of adverse reactions was not significantly different between the two groups (P>0.05).【Conclusion】 The combination of Shenmai Injection with Entecavir is significantly effective in treating patients with hepatitis B-related compensated cirrhosis. It can improve liver function and it is safe and reliable, making it worthy of clinical application and promotion.
李晓梅, 皇甫朵娟. 参麦注射液联合恩替卡韦治疗乙肝肝硬化代偿期患者的疗效[J]. 医学临床研究, 2024, 41(4): 562-564.
LI Xiaomei, HUANGFU Duojuan. The Efficacy of Shenmai Injection Combined with Entecavir in Treating Patients with Hepatitis B-Related Compensated Cirrhosis. JOURNAL OF CLINICAL RESEARCH, 2024, 41(4): 562-564.
[1] CHATURVEDI V K, SINGH A, DUBEY S K, et al. Molecular mechanistic insight of hepatitis B virus mediated hepatocellular carcinoma[J].Microb Pathog,2019,128(1):184-194. [2] IANNACONE M, GUIDOTTI L G. Immunobiology and pathogenesis of hepatitis B virus infection[J].Nat Rev Immunol,2022,22(1):19-32. [3] BARILI V, BONI C, ROSSI M, et al. Metabolic regulation of the HBV-specific T cell function[J].Antiviral Res,2021,185(3):1049. [4] SUEMITSU SHINSUKE, MIYAOKA YOUICHI, KODAMA YASUHIDE. KASL clinical practice guidelines for management of chronic hepatitis B[J].Clin Mol Hepatol,2022, 28(2):124. [5] KIM J H. 2018 Korean Association for the Study of the Liver (KASL) Clinical Practice Guidelines of Chronic Hepatitis B: What's Different[J].Korean J Gastroenterol,2019, 73(3):132-140. [6] 葛冰景,周薏,肖铁刚,等. 逍遥散联合恩替卡韦对肝郁脾虚型乙型肝炎肝硬化代偿期患者纤维化及铁代谢的影响[J].湖南中医药大学学报,2021,41(2):296-302. [7] 吕奕,王毓麟. 参麦注射液联合阿德福韦酯治疗乙肝肝硬化失代偿期的疗效[J].医学信息,2020,33(6):162-163. [8] 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J].中华肝脏病杂志, 2019, 27(12):938-961. [9] VYAS A K, JINDAL A. Concerns and safety of add-on versus switch peginterferon therapy for chronic hepatitis B[J].Clin Gastroenterol Hepatol,2021, 20(5):1465. [10] PAUL S, CHAKRABORTY S, ANAND U, et al. Withania somnifera (L.) Dunal (Ashwagandha): A comprehensive review on ethnopharmacology, pharmacotherapeutics, biomedicinal and toxicological aspects[J].Biomed Pharmacother,2021, 143(2):1175. [11] 边倩,解新科,寇小妮,等. 软肝化瘀饮辅助恩替卡韦分散片治疗慢性乙型肝炎肝硬化代偿期瘀血阻络证临床研究[J].中国中医药信息杂志,2021,28(3):94-99. [12] 丁帅,王喜,商红卫. 参麦注射液联合阿德福韦酯治疗乙肝肝硬化失代偿期的疗效观察[J].现代诊断与治疗,2018,29(10):1547-1549. [13] 赵华歌,吴峥嵘. 美能联合参脉注射液治疗乙肝肝硬化30例[J].医药论坛杂志,2019,32(6):151-152. [14] 崔东方. 参麦注射液联合拉米夫定治疗失代偿乙肝肝硬化的临床疗效及其对患者肝功能的影响观察[J].北方药学,2017,14(3):46-47. [15] 刘晓东,郭晓会,任海霞,等. 参麦注射液联合三七粉治疗肝硬化食管胃静脉曲张出血疗效及对凝血和免疫功能的影响[J].现代中西医结合杂志,2021,30(33):3688-3691. [16] 蔡亚军,姚仲彩,皮文妍. 参麦注射液联合化疗对肺癌合并肝硬化患者ALB、PAB及LMR的影响[J].广东医学,2020,41(10):1047-1050.
2024, Vol. 41 
